This is a guest blog by Danielle Pouletsos. She completed her BS in Health Science with a concentration in Public Health and Community Health Education in 2005. She earned her Master of Public Health degree at the University of Illinois at Chicago and specialized in Public Health Informatics in 2009. She has worked in the non-profit sector for over 10 years serving those with HIV/AIDS and Developmental Disabilities.
Read more about public health, mhealth and related topics on Danielle’s blog.This is part 1 of a two part series that explores the real world impact of mHealth.
Part I – The Hassle of Anticoagulation Management
Warfarin, or Coumadin, is the most widely prescribed anticoagulant and has been on the pharmaceutical market for about 60 years. Anticoagulation therapy saves many lives each year, but also poses extreme health risks from side effects, mismanagement, and birth defects. Termed a “blood-thinner,” Warfarin inhibits the production of Vitamin K in the body, which is essential for the body’s natural blood clotting cascade. There are a variety of diagnoses that will influence practitioners to decide whether or not to place a patient on anticoagulation therapy, either for short term, or chronic use. There are also multiple diagnoses in which Warfarin therapy is the patient’s only option.